InvestorsHub Logo
Followers 1321
Posts 247191
Boards Moderated 52
Alias Born 12/07/2009

Re: None

Monday, 05/20/2019 12:10:47 PM

Monday, May 20, 2019 12:10:47 PM

Post# of 1220
$BIXT Future use of the MDX Viewer likely to start in operating rooms, clinical trials to measure tissue balance in stroke, and to test the viability of an organ before transplantation

BOSTON, MASSACHUSETTS, May 20, 2019 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), a developmental stage biotechnology company with a pipeline of anti-necrosis drugs designed to treat hypoxia by delivering a small molecule carrying oxygen to the brain of stroke victims announced today that the Journal of Emergency Medicine and Care published a peer reviewed article that describes a revolutionary new vital sign called the Tissue Metabolic Score (TMS).

https://finance.yahoo.com/news/bioxytran-using-paradigm-changing-vital-110533064.html


ALL comments are In My Own OPINION. Please Use Your Own DD for Stock Trading.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BIXT News